Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
INTS
$3.96
-1.00%
INTS · Intensity Therapeutics, Inc.
$3.96
-0.04 (-1.00%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our balances in cash and cash equivalents, our ability to continue our operations is dependent on obtaining additional capital, which is not within our control. As a result, we believe there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$12.93M
Shares
3.26M
All earnings calls
Earnings call · FY2023 Q2
Intensity Therapeutics, Inc. Q2 FY2023 Earnings Call
Intensity Therapeutics, Inc. Q2 FY2023 Earnings Call
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Diluted EPS
-$35.75
Net income
-$3.70M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 14, 2023 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 14, 2023 · complete as-filed document